Turnstone Biologics and National Cancer Institute Enters into a R&D Agreement to Study TIL Therapy + Viral Immunotherapy for Solid Tumors
Shots:
- Both the organisations will evaluate the generation of 'Selected TILs' from clinical tissue samples obtained from patients treated with Turnstone’s proprietary viral immunotx. to enhance the efficacy of TILs and to extend their benefit to patients with solid tumors
- Turnstone will be responsible for manufacturing and administering viral immunotx. to patients and subsequent tissue collection and NCI will use its in vitro techniques to study lymphocytes derived from these patients, characterize their specificity, and evaluate their persistence, under the terms of CRADA
- The data will be analyzed jointly and exchange information and expertise for the development of oncolytic viruses as an improved method for the generation of 'Selected TILs'
Ref: Businesswire | Image: Turnstone Biologics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
